X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (1899) 1899
animals (1418) 1418
dipeptidyl-peptidase iv inhibitors - pharmacology (1058) 1058
male (1007) 1007
diabetes mellitus, type 2 - drug therapy (978) 978
pharmacology & pharmacy (937) 937
dipeptidyl-peptidase iv inhibitors - therapeutic use (746) 746
dipeptidyl peptidase 4 - metabolism (737) 737
glucagon-like peptide-1 (692) 692
type 2 diabetes (639) 639
rats (577) 577
diabetes (560) 560
female (560) 560
hypoglycemic agents - therapeutic use (539) 539
mice (517) 517
hypoglycemic agents - pharmacology (513) 513
sitagliptin (447) 447
endocrinology & metabolism (436) 436
chemistry, medicinal (356) 356
middle aged (355) 355
glucose (346) 346
adamantane - analogs & derivatives (344) 344
biochemistry & molecular biology (328) 328
adult (295) 295
double-blind (293) 293
insulin (282) 282
dipeptidyl peptidase-4 inhibitor (279) 279
analysis (278) 278
dipeptidyl peptidase-iv (278) 278
dipeptidyl-peptidase iv inhibitors - adverse effects (276) 276
sitagliptin phosphate (270) 270
diabetes mellitus (269) 269
dipeptidyl-peptidase iv inhibitors - administration & dosage (266) 266
dipeptidyl-peptidase-iv (265) 265
blood glucose - metabolism (259) 259
hypoglycemic agents (256) 256
vildagliptin (255) 255
aged (248) 248
dipeptidyl peptidase iv (248) 248
blood glucose - drug effects (246) 246
glycemic control (244) 244
metformin (244) 244
diabetes mellitus, type 2 - blood (234) 234
glp-1 (231) 231
treatment outcome (224) 224
peptides (223) 223
internal medicine (222) 222
pyrrolidines - pharmacology (222) 222
structure-activity relationship (222) 222
peptidase (221) 221
type-2 diabetes-mellitus (220) 220
research (219) 219
dipeptidyl-peptidase iv inhibitors - pharmacokinetics (216) 216
hypoglycemic agents - adverse effects (212) 212
dipeptidyl-peptidase iv inhibitors (211) 211
dipeptidyl-peptidase iv inhibitors - chemistry (210) 210
mice, inbred c57bl (207) 207
diabetes mellitus, type 2 - metabolism (202) 202
dose-response relationship, drug (201) 201
expression (201) 201
inhibitors (201) 201
glucagon (200) 200
drug therapy, combination (198) 198
adamantane - pharmacology (195) 195
care and treatment (194) 194
dpp-4 inhibitor (194) 194
pharmacokinetics (194) 194
type 2 diabetes mellitus (194) 194
hypoglycemic agents - administration & dosage (190) 190
linagliptin (190) 190
triazoles - pharmacology (190) 190
protease inhibitors - pharmacology (189) 189
rats, wistar (185) 185
safety (178) 178
cd26 (177) 177
beta-cell function (176) 176
pyrazines - pharmacology (176) 176
dipeptidyl peptidase 4 (169) 169
medicine & public health (168) 168
medicine, research & experimental (168) 168
nitriles - pharmacology (168) 168
dipeptidyl peptidase-4 inhibitors (164) 164
administration, oral (163) 163
enzymes (163) 163
glucagon-like peptide 1 - metabolism (163) 163
drug therapy (156) 156
efficacy (154) 154
dipeptidyl peptidase 4 - chemistry (152) 152
inflammation (151) 151
enzyme inhibitors - pharmacology (150) 150
insulin resistance (150) 150
dextrose (149) 149
physiological aspects (149) 149
risk factors (149) 149
adamantane - therapeutic use (147) 147
disease models, animal (147) 147
cell biology (146) 146
health aspects (146) 146
insulin - metabolism (146) 146
improves glycemic control (144) 144
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2865) 2865
Japanese (32) 32
German (13) 13
French (11) 11
Spanish (10) 10
Chinese (8) 8
Russian (7) 7
Hungarian (6) 6
Danish (2) 2
Korean (1) 1
Polish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Clinical and Experimental Pharmacology and Physiology, ISSN 0305-1870, 01/2008, Volume 35, Issue 1, pp. 29 - 34
SUMMARY • The aim of the present study was to determine whether inhibition of dipeptidyl peptidase IV (DPP IV... 
3-N-[(2S,3S)-2-amino-3-methylpentanoyl]-1,3-thiazolidine | N2-(diphenylacetyl)-N-[(4-hydroxyphenyl)methyl]-d-arginine amide | P32/98 | Wistar-Kyoto rat | neuropeptide Y | dipeptidyl peptidase IV | spontaneously hypertensive rat | Y1 receptor | BIBP 3226 | peptide YY | 3‐N‐[(2S,3S)‐2‐amino‐3‐methylpentanoyl]‐1,3‐thiazolidine | Wistar‐Kyoto rat | N2‐(diphenylacetyl)‐N‐[(4‐hydroxyphenyl)methyl]‐d‐arginine amide | BIBP 3226 | Neuropeptide Y | Spontaneously hypertensive rat | N2-(diphenylacetyl)-N-[(4-hydroxyphenyl)methyl]-D- arginine amide | Peptide YY | Dipeptidyl peptidase IV | PHYSIOLOGY | SPONTANEOUSLY HYPERTENSIVE-RATS | NHE3 | NEUROPEPTIDE-Y | N2-(diphenylacetyl)-N-[(4-hydroxyphenyl)methyl]-D-arginine amide | PHARMACOLOGY & PHARMACY | RECEPTORS | NORADRENALINE | Y-1 receptor | GLUCOSE-TOLERANCE | VASOCONSTRICTION | Antihypertensive Agents - pharmacology | Dipeptidyl Peptidase 4 - metabolism | Captopril - pharmacology | Hydralazine - pharmacology | Dipeptidyl-Peptidase IV Inhibitors - therapeutic use | Rats, Inbred WKY | Receptors, Neuropeptide Y - metabolism | Hypertension - drug therapy | Ganglionic Blockers - pharmacology | Dipeptidyl-Peptidase IV Inhibitors - pharmacology | Arginine - analogs & derivatives | Dose-Response Relationship, Drug | Drug Interactions | Receptors, Neuropeptide Y - drug effects | Pentanoic Acids - pharmacology | Angiotensin-Converting Enzyme Inhibitors - pharmacology | Blood Pressure - drug effects | Hypertension - enzymology | Hypertension - genetics | Thiazolidines - pharmacology | Disease Models, Animal | Chlorisondamine - pharmacology | Rats, Inbred SHR | Vasodilator Agents - pharmacology | Rats | Antihypertensive Agents - therapeutic use | Hypertension - physiopathology | Animals | Arginine - pharmacology | Receptors, Neuropeptide Y, drug effects | Antihypertensive Agents, therapeutic use | Hypertension, enzymology | Arginine, pharmacology | Hypertension, drug therapy | Arginine, analogs and derivatives | Hypertension, genetics | Pentanoic Acids, pharmacology | Captopril, pharmacology | Vasodilator Agents, pharmacology | Ganglionic Blockers, pharmacology | Hypertension, physiopathology | Blood Pressure, drug effects | Dipeptidyl-Peptidase IV Inhibitors, therapeutic use | Angiotensin-Converting Enzyme Inhibitors, pharmacology | Antihypertensive Agents, pharmacology | Chlorisondamine, pharmacology | Receptors, Neuropeptide Y, metabolism | Hydralazine, pharmacology | Dipeptidyl-Peptidase IV Inhibitors, pharmacology | Thiazolidines, pharmacology | Antigens, CD26, metabolism | Antigens, CD26, antagonists and inhibitors | Hypertension | Blood pressure | Captopril | Analysis
Journal Article
Journal of medicinal chemistry, ISSN 0022-2623, 04/2014, Volume 57, Issue 8, pp. 3205 - 3212
Journal Article
Nature reviews. Endocrinology, ISSN 1759-5037, 2016, Volume 12, Issue 10, pp. 566 - 592
Journal Article
PloS one, ISSN 1932-6203, 11/2016, Volume 11, Issue 11, p. e0166275
Journal Article
Clinical and Experimental Pharmacology and Physiology, ISSN 0305-1870, 10/2015, Volume 42, Issue 10, pp. 999 - 1024
Journal Article
Journal of medicinal chemistry, ISSN 0022-2623, 01/2005, Volume 48, Issue 1, pp. 141 - 151
Journal Article